Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B

Suzuki, Kazuharu; Suda, Goki; Yamamoto, Yoshiya et al.

PLoS ONE, 2022, 17(1), e0261760

Permalink : https://hdl.handle.net/2115/86937

このアイテムのアクセス数:406件（2026-10-17 09:16 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
https://doi.org/10.1371/journal.pone.0261760     44

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権
open access
URI
https://hdl.handle.net/2115/86937
タイトル
Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B
著者
Suzuki, Kazuharu ; Suda, Goki ; Yamamoto, Yoshiya ; Abiko, Satoshi ; Kinoshita, Kenji ; Miyamoto, Shuichi ; Sugiura, Ryo ; Kimura, Megumi ; Maehara, Osamu ; Yamada, Ren ; Kitagataya, Takashi ; Shigesawa, Taku ; Ohara, Masatsugu ; Kawagishi, Naoki ; Nakai, Masato ; Sho, Takuya ; Natsuizaka, Mitsuteru ; Morikawa, Kenichi ; Ogawa, Koji ; Sakamoto, Naoya
著者名
Suzuki, Kazuharu
e-Rad_Researcher
20447460
著者名
Suda, Goki
著者名
Yamamoto, Yoshiya
著者名
Abiko, Satoshi
著者名
Kinoshita, Kenji
著者名
Miyamoto, Shuichi
著者名
Sugiura, Ryo
著者名
Kimura, Megumi
著者名
Maehara, Osamu
著者名
Yamada, Ren
著者名
Kitagataya, Takashi
著者名
Shigesawa, Taku
著者名
Ohara, Masatsugu
著者名
Kawagishi, Naoki
著者名
Nakai, Masato
著者名
Sho, Takuya
著者名
Natsuizaka, Mitsuteru
著者名
Morikawa, Kenichi
著者名
Ogawa, Koji
e-Rad_Researcher
10334418
著者名
Sakamoto, Naoya
言語
英語
発行日
2022-01-20
出版者
PLOS
収録物名
PLoS ONE
巻(号)
17(1)
ページ
e0261760
抄録
For long-term treatment of hepatitis B virus (HBV) infection, switching from tenofovir-disoproxil-fumarate (TDF) to tenofovir-alafenamide (TAF) may prevent renal dysfunction and bone loss. However, the precise effects of this switch on the blood lipid profile remain to be clarified. This is an important issue as TDF is known to have effects on both low- and high-density lipids. Therefore, our retrospective multi-center study aimed to evaluate the effects of switching from TDF to TAF on the lipid profile of patients with HBV infection. Samples were obtained prior to the switch from TDF to TAF and at 6-12 months after TAF initiation. In some cases, additional samples obtained pre- and post-TDF administration were available for analysis. Serum cholesterol levels, including oxidized-low-density lipoprotein (LDL) and non-high-density lipoprotein-cholesterol (HDL-c), and the rate of dyslipidemia, according to the NCEP-ATP III lipid risk classification, were analyzed. The data from 69 patients were analyzed, including 33 patients with pre- and post-TDF-initiation serum samples. Total cholesterol (T-chol), HDL-c, LDL-c, non-HDL-c, and oxidized LDL levels increased significantly after switching to TAF. With regard to sequential changes pre- to post-TAF, TDF was associated with significantly lower serum T-chol, HDL-c, and oxidized LDL-c levels, with T-chol, HDL-c, LDL-c, and oxidized LDL-c levels increasing significantly after the switch. The switch from TDF to TAF was also associated with an increase in the rate of dyslipidemia, from 33% to 39%, with an increase in the rate of severe dyslipidemia of 1.4% and 5.8%, based on T-chol and LDL-c levels. Of note, no cases of severe dyslipidemia were detected pre-TAF treatment. As oxidized LDL-c and non-HDL-c are strongly associated with atherosclerosis development, careful monitoring of lipid is needed after switching from TDF to TAF in this clinical population.
資源タイプ
学術雑誌論文
出版タイプ
Version of Record
PISSN
1932-6203
関連情報 (isIdenticalTo)
出版社版DOI
https://doi.org/10.1371/journal.pone.0261760